Bris­tol-My­ers Squibb boasts im­pres­sive 5-year melanoma OS da­ta on Op­di­vo/Yer­voy com­bo, though it still can't pin­point who should take it

BARCELONA — Two years ago Bris­tol-My­ers Squibb took the stage at AACR to show­case some im­pres­sive 5-year sur­vival rates with Op­di­vo, un­der­scor­ing the dura­bil­i­ty of the PD-1 in­hibitor and flag­ging tu­mor mu­ta­tion bur­den as a po­ten­tial bio­mark­er to pre­dict re­sponse. At ES­MO Con­gress 2019, the spot­light is on melanoma — but the search for a pre­dic­tive sig­nal seems ever elu­sive.

Now the longest Phase III fol­low-up in­volv­ing a check­point com­bo, the 5-year OS dat­a­cut of Check­mate-067 ex­tends an im­pres­sive streak on dis­play the year be­fore. Among 945 pa­tients with stage III and IV melanoma split in­to three equal groups, the rates are 52% for Op­di­vo plus Yer­voy, 44% for Op­di­vo, and 26% for Yer­voy (For ref­er­ence, at 4 years the com­bo scored 53%, Op­di­vo alone had 46%, while Yer­voy monother­a­py reg­is­tered 30%).

To un­der­stand how re­mark­able this is, one must re­vis­it the past, said study au­thor James Larkin in an ES­MO state­ment, when metasta­t­ic melanoma was con­sid­ered un­treat­able.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA